Wythehi Ambihapathy

Direct to Patient Testing at Cancer Diagnosis for Precision Prevention-2 (DETECT-2): protocol for a two-arm equivalence UK multi-centre randomised controlled trial evaluating uptake of genetic testing

Caitlin T. Fierheller, Priyanka Deshmukh, Ashwin Kalra, Hamda Mohamed et autres

Background Mainstreaming ovarian, endometrial, and colorectal cancer patients, in the context of genetic-testing at cancer diagnosis, involves pre-test counselling, consent, and return of results by the clinical cancer team, which uses significant clinician time and resources. Alternative implementation strategies might be more …

gb, us (code pays fourni par la source)

Protocol for the DETECT-2 randomised controlled trial: a comparison of direct-to-patient versus mainstreaming genetic testing at ovarian, endometrial and colorectal cancer diagnosis

Caitlin T. Fierheller, Priyanka Deshmukh, Ashwin Kalra, Hamda Mohamed et autres

gb (code pays fourni par la source)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)

Grace Li, Natalie G. Marchevsky, Grace C. Macaulay, Parvinder K. Aley et autres

BACKGROUND: Paediatric COVID-19 vaccination programmes were initiated in response to the coronavirus pandemic declared by the World Health Organisation (WHO) in 2020. Ten COVID-19 vaccines received WHO Emergency Use Listing, however, only five were approved for use in children. ChAdOx1 nCoV-19 (AZD1222) …

gb, cn (code pays fourni par la source)

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair Munro, Shuo Feng, Leila Janani, Victoria Cornelius et autres

BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19. METHODS: The COV-BOOST …

gb (code pays fourni par la source)